SD BioSensor

SD BioSensor Inc., an in-vitro diagnostic company, provides point-of-care diagnostic solutions in South Korea and internationally. The company's products include STANDARD Q, which provides various rapid test parameters comprising COVID-19 products and other parameters; STANDARD F, a multi-parametric and random accessible FIA system that provides diagnostic results to the laboratories; and STANDARD E, an enzyme linked immunosorbent assay for mass screening tests. Its products also include STANDARD M, a point-of-care MDx system for clinical decision making near-the-patient, which include analyzers, assay menus, qPCR reagents, and NA extraction kits; procell Dx, an in vitro diagnostic products for the diagnosis of infectious disease, such as tuberculosis and SARS-CoV-2, and for checking the immune status of individuals through the interferon gamma release assay; and blood glucose meters. The company was founded in 2010 and is headquartered in Suwon, South Korea.

Our mission is to help create a healthier, safer world by merging the most advanced medical technologies with practical, insightful industry experience.

We envision a world where everyone has access to advanced medical technologies that enable earlier diagnosis, improved treatments, and better outcomes for patients.

SD BioSensor has won numerous awards including the Top 10 Innovative Robotics & Machines Award from the IEEE Robotics and Automation Society, the Innovate UK-Home Office Award, and the Fujifilm Research Award.